Key result
The extravascular StarClose SE device was associated with a lower rate of overall bleeding complications compared to the intravascular AngioSeal device at 30 days post-PCI.
Why the study?
Vascular closure devices are frequently used after PCI to prevent access site bleeding, but direct comparisons between mechanistically different types of femoral closure devices were needed.
Does the intravascular AngioSeal device compared to the extravascular StarClose SE device reduce bleeding complications in patients undergoing PCI?
Observational (n=400)
Open-label
No
Does the intravascular AngioSeal device compared to the extravascular StarClose SE device reduce bleeding complications in patients undergoing PCI?
In patients undergoing PCI, the intravascular AngioSeal device was associated with higher rates of bleeding complications compared to the extravascular StarClose SE device, with no difference in 30-day MACE.
Answers are grounded in this paper and cite their sources.
Extravascular closure was associated with fewer bleeds than intravascular post-PCI; leaves open whether RCTs will confirm before practice change.
Background: Various types of vascular closure devices (VCDs) are frequently utilized in patients undergoing percutaneous coronary intervention (PCI) in order to prevent arterial access site bleeding, which represents one of the most relevant complications associated with adverse clinical outcomes. This study aims to compare directly two mechanistically different types of femoral closure (FC) devices in patients undergoing PCI. Methods: This single-center, prospective, observational study includes consecutively patients either treated by the extravascular StarClose SE (Abbott, Illinois, U.S.A.) or the intravascular AngioSeal FC (St. Jude Medical, Inc., St. Paul, MN, U.S.A.) after PCI. The primary endpoint was bleeding complications, the secondary endpoint was major adverse cardiac events (MACE) at 30 days of follow-up. Results: 200 patients in each group (StarClose SE and AngioSeal) were enrolled following PCI. The rates of overall and non-access site bleedings were significantly higher in the AngioSeal group (56%; 6%) compared to the StarClose SE group (43.5%; 0.5%) (p = 0.012; 0.003). Additionally, complicated access site bleedings were also significantly higher in the AngioSeal group (p = 0.011). No significant differences of MACE were observed in both groups. However, there was a higher rate of unsuccessful implantation of the StarClose SE (n=12, excluded from the study). Conclusions: In case of successful implantation, FC by the AngioSeal is associated with the higher rate of both access and non-access site bleedings, but similar rates of MACE at 30 days compared to the StarClose SE device.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) conducted an observational in Patients undergoing percutaneous coronary intervention (PCI) (n=400). StarClose SE (extravascular femoral closure device) vs. AngioSeal (intravascular femoral closure device) was evaluated on Overall rate of all relevant access site and non-access site bleedings within 30 days (p=0.012). The extravascular StarClose SE device was associated with a lower rate of overall bleeding complications compared to the intravascular AngioSeal device at 30 days post-PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: